Table 2.

Risk of colorectal cancer associated with percent genomic leukocyte DNA methylation levels (or %5-mC), the PLCO Cancer Screening Trial, 1993–2001

Cases (N = 370)Controls (N = 493)
%5-mCnn%5-mC cutoffOR (95% CI)
Tertile
 Third104160≥4.111.00
 Second1461673.95–<4.111.44 (1.02–2.03)
 First120166<3.951.14 (0.80–1.63)
Ptrend0.51

NOTE: ORs and 95% CIs calculated by unconditional logistic regression adjusted for age, gender, race, time since initial sigmoidoscopy screening, year of randomization, smoking, body mass index, use of NSAIDs, a family history of colorectal cancer, and a prior history of adenoma, hyperplastic polyps, or inflammatory bowel disease or polyposis syndrome (i.e., ulcerative colitis, Crohn disease, Gardner syndrome, and familial polyposis).